시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 중증급성호흡기증후군(SARS) 치료 시장 보고서(2025년)
Severe Acute Respiratory-Syndrome Treatment Global Market Report 2025
상품코드 : 1694993
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,342,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,167,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,992,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

중증급성호흡기증후군(SARS) 치료 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 15.8%로 성장할 전망이며, 71억 5,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 광역 항바이러스제, 새로운 치료제, 백신의 진보, 팬데믹 대책에 기인하고 있습니다. 예측 기간 주요 동향에는 RNA 표적 치료제, AI 신약, 세계 공동 연구 및 공중 보건 교육 등이 있습니다.

호흡기 질환의 유병률 증가는 향후 수년간 중증급성호흡기증후군(SARS) 치료 시장의 성장을 가속할 것으로 예상됩니다. 호흡기 질환에는 호흡을 관장하고 신체와 환경 사이의 가스 교환을 촉진하는 호흡기 계통에 영향을 미치는 다양한 질환이 포함됩니다. 중증급성호흡기증후군 치료는 증상 완화, 호흡부전 예방, 염증 경감 및 산소 농도 유지를 목적으로 하고 있습니다. 예를 들면, 2023년 11월, 오스트레일리아를 거점으로 하는 천식 케어에 특화한 비영리 단체 National Asthma Council은, 2022년의 천식 관련 사망자수를 467명(이중 여성 299명, 남성 168명)이라고 보고했습니다. 이는 2021년에 기록된 사망자 수 355명에서 증가했습니다. 따라서 호흡기 질환의 발생률 상승이 중증급성호흡기증후군 치료 시장의 성장을 촉진하고 있습니다.

연구개발에 대한 투자의 급증은 향후 중증급성호흡기증후군 치료 시장의 성장 기폭제가 될 것으로 생각되고 있습니다. 연구개발에 대한 투자는 종종 R&D로 줄여지며, 신선한 지식 발굴을 목적으로 한 체계적이고 혁신적인 조사 및 이니셔티브를 실시하는 것을 목적으로 한 조직, 정부 또는 단체에 의한 재원과 인적 전문지식의 할당에 관계됩니다. 연구개발 투자 강화는 사스나 코로나19와 같은 질환을 포함한 중증급성호흡기증후군의 치료법을 진보시키는 데 매우 중요한 역할을 담당하고 있습니다. 이러한 투자는 효과적인 의약품, 백신, 진단 도구, 치료 전략을 수립하는 데 기여하며, 궁극적으로 환자의 회귀를 개선하고 세계 건강에 대한 대비를 강화합니다. 주목해야 할 것은 2023년 8월 미국 연방정부의 행정부인 미국 보건사회복지부(Department of Health and Human Services: HHS)가 전략적 준비 및 대응국(Administration for Strategic Preparedness and Response: ASPR)과 공동으로 프로젝트 넥스트젠(Project NextGen)에 14억 달러 이상을 할당했다고 밝힌 것입니다. 이 이니셔티브는 차세대 코로나19 백신 및 치료법 개발을 지원하는 것을 목적으로 하고 있습니다. 그 결과 연구개발 투자 증가가 중증급성호흡기증후군 치료 시장 성장의 매우 중요한 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장-금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Severe acute respiratory syndrome (SARS) is a severe type of pneumonia caused by an airborne virus that can be transmitted through tiny droplets of saliva. This previously unidentified virus belongs to the Coronaviridae family and is known as SARS-associated COVID-19 (SARS-CoV). The treatment for severe acute respiratory syndrome (SARS) involves medical interventions and supportive measures aimed at managing the symptoms and complications of this viral respiratory illness.

The primary classes of drugs used in the treatment of severe acute respiratory syndrome include antibiotics, antivirals, corticosteroids, monoclonal antibodies, and others. Antibiotics are a class of medications used to treat bacterial infections. They function by either killing bacteria or inhibiting their growth, depending on the specific type of antibiotic. In the context of severe acute respiratory syndrome caused by SARS-CoV and SARS-CoV-2, these antibiotics are administered orally and intravenously. They are distributed through various channels, including hospital pharmacies and retail pharmacies, among others.

The severe acute respiratory syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides severe acute respiratory-syndrome treatment market statistics, including severe acute respiratory-syndrome treatment industry global market size, regional shares, competitors with a severe acute respiratory syndrome treatment market share, detailed severe acute respiratory-syndrome treatment market segments, market trends and opportunities and any further data you may need to thrive in the severe acute respiratory-syndrome treatment industry. This severe acute respiratory-syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The severe acute respiratory-syndrome treatment market size has grown rapidly in recent years. It will grow from $3.45 billion in 2024 to $3.97 billion in 2025 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to global outbreak response, antiviral drug development, vaccine development, public health preparedness.

The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $7.15 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to broad-spectrum antivirals, emerging therapeutics, vaccine advancements, pandemic preparedness. Major trends in the forecast period include rna-targeted therapies, ai in drug discovery, global collaborations, public health education.

The increasing prevalence of respiratory diseases is expected to drive the growth of the severe acute respiratory syndrome (SARS) treatment market in the coming years. Respiratory diseases encompass a range of conditions that affect the respiratory system, which is responsible for breathing and facilitating gas exchange between the body and the environment. Treatments for severe acute respiratory syndrome aim to alleviate symptoms, prevent respiratory failure, reduce inflammation, and maintain oxygen levels. For example, in November 2023, the National Asthma Council, an Australia-based non-profit organization focused on asthma care, reported 467 asthma-related deaths in 2022, including 299 females and 168 males. This marked an increase from the 355 deaths recorded in 2021. Therefore, the rising incidence of respiratory diseases is fueling the growth of the severe acute respiratory syndrome treatment market.

The progressive surge in investments in research and development is poised to be a catalyst for the growth of the severe acute respiratory syndrome treatment market in the near future. These investments in research and development, often abbreviated as R&D, pertain to the allocation of financial resources and human expertise by organizations, governments, or entities with the aim of conducting systematic and innovative investigations and initiatives, with the goal of unearthing fresh knowledge. Augmented R&D investments play a pivotal role in advancing the array of available treatment options for severe acute respiratory syndromes, including conditions like SARS and COVID-19. Such investments contribute to the formulation of effective drugs, vaccines, diagnostic tools, and therapeutic strategies, ultimately enhancing patient outcomes and reinforcing global health preparedness. Notably, in August 2023, the United States Department of Health and Human Services, the executive branch department of the U.S. federal government, disclosed that the U.S. Department of Health and Human Services (HHS), in collaboration with the Administration for Strategic Preparedness and Response (ASPR), had allocated over $1.4 billion for Project NextGen. This initiative aims to support the development of the next generation of COVID-19 vaccines and treatments. Consequently, the increasing investments in research and development are the pivotal driving force behind the growth of the severe acute respiratory syndrome treatment market.

Leading companies actively participating in the severe acute respiratory syndrome treatment market are at the forefront of introducing innovative techniques, with a notable example being multiplexed real-time PCR. Multiplexed real-time PCR is a molecular biology technology that facilitates the simultaneous amplification and detection of multiple DNA or RNA targets in a single procedure. A case in point is the product launched by TransGen Biotech Co. Ltd., a Beijing-based manufacturer and researcher of molecular and cellular biology products, in July 2022. They introduced the Trans-SARS-CoV-2, Influenza A and B, and Respiratory Syncytial Virus Assay. This groundbreaking assay is designed as a multiplexed real-time PCR (polymerase chain reaction) assay, capable of detecting and distinguishing severe acute respiratory syndrome COVID-19 2 (SARS-CoV-2), Influenza A, Influenza B, and respiratory syncytial virus (RSV) in a single specimen. This innovative tool plays a crucial role in the diagnosis and treatment of severe acute respiratory syndromes, including COVID-19, influenza, and RSV, thus aiding in guiding treatment decisions and preventing the spread of these diseases.

In March 2022, AbbVie Inc., a U.S.-based pharmaceutical company, established a collaboration with Scripps Research, an independent, non-profit biomedical research and drug discovery institute also based in the United States. This strategic partnership is geared toward the development of cutting-edge direct-acting antiviral therapies designed for the treatment of COVID-19. The collaboration aims to pioneer innovative solutions for combatting the virus.

Major companies operating in the severe acute respiratory-syndrome treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.

North America was the largest region in the severe acute respiratory syndrome treatment market in 2024. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the severe acute respiratory syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The severe acute respiratory syndrome treatment market consists of revenues earned by entities by providing services such as respiratory therapy, oxygen therapy, ventilation, intensive care, isolation and infection control, fluid and electrolyte management and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The severe acute respiratory syndrome treatment market also includes sales of azithromycin, immunomodulators, vaccines, ribavirin, ritonavir, remdesivir, methylprednisolone, prednisolone, dexamethasone and interferon. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Severe Acute Respiratory-Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on severe acute respiratory-syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for severe acute respiratory-syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The severe acute respiratory-syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Severe Acute Respiratory-Syndrome Treatment Market Characteristics

3. Severe Acute Respiratory-Syndrome Treatment Market Trends And Strategies

4. Severe Acute Respiratory-Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Severe Acute Respiratory-Syndrome Treatment Growth Analysis And Strategic Analysis Framework

6. Severe Acute Respiratory-Syndrome Treatment Market Segmentation

7. Severe Acute Respiratory-Syndrome Treatment Market Regional And Country Analysis

8. Asia-Pacific Severe Acute Respiratory-Syndrome Treatment Market

9. China Severe Acute Respiratory-Syndrome Treatment Market

10. India Severe Acute Respiratory-Syndrome Treatment Market

11. Japan Severe Acute Respiratory-Syndrome Treatment Market

12. Australia Severe Acute Respiratory-Syndrome Treatment Market

13. Indonesia Severe Acute Respiratory-Syndrome Treatment Market

14. South Korea Severe Acute Respiratory-Syndrome Treatment Market

15. Western Europe Severe Acute Respiratory-Syndrome Treatment Market

16. UK Severe Acute Respiratory-Syndrome Treatment Market

17. Germany Severe Acute Respiratory-Syndrome Treatment Market

18. France Severe Acute Respiratory-Syndrome Treatment Market

19. Italy Severe Acute Respiratory-Syndrome Treatment Market

20. Spain Severe Acute Respiratory-Syndrome Treatment Market

21. Eastern Europe Severe Acute Respiratory-Syndrome Treatment Market

22. Russia Severe Acute Respiratory-Syndrome Treatment Market

23. North America Severe Acute Respiratory-Syndrome Treatment Market

24. USA Severe Acute Respiratory-Syndrome Treatment Market

25. Canada Severe Acute Respiratory-Syndrome Treatment Market

26. South America Severe Acute Respiratory-Syndrome Treatment Market

27. Brazil Severe Acute Respiratory-Syndrome Treatment Market

28. Middle East Severe Acute Respiratory-Syndrome Treatment Market

29. Africa Severe Acute Respiratory-Syndrome Treatment Market

30. Severe Acute Respiratory-Syndrome Treatment Market Competitive Landscape And Company Profiles

31. Severe Acute Respiratory-Syndrome Treatment Market Other Major And Innovative Companies

32. Global Severe Acute Respiratory-Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Severe Acute Respiratory-Syndrome Treatment Market

34. Recent Developments In The Severe Acute Respiratory-Syndrome Treatment Market

35. Severe Acute Respiratory-Syndrome Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기